The Trump administration is expected to announce tariffs on pharmaceuticals "in the next month or two," an official said. | ...

Luveltamab tazevibulin demonstrated activity in an ongoing phase 2/3 trial of patients with FRα-positive, platinum-resistant ovarian cancer.

DelveInsight's "FYARRO Market Size, Forecast, and Market Insight Report" highlights the details around FYARRO, an mTOR inhibitor. The report provides product descriptions, patent details, and ...

The logo of Lilly is seen on a wall of the Lilly France company unit, part of the Eli Lilly and Co drugmaker group, in Fegersheim near Strasbourg, France, February 1, 2018. Picture taken February ...

FYARRO holds strong market potential, particularly in treating rare and aggressive cancers like PEComa, where treatment options are limited. As the first FDA-approved therapy for advanced PEComa ...

Trump to approve land swap for Rio Tinto copper mine opposed by Native Americans The Trump administration said on Thursday it would approve a land swap needed for Rio Tinto and BHP to build one of ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

The current price of Dai (DAI) is $1.00, as of Apr 18, 2025. Over the last 24 hours, the price has moved by 0.02%, with a change of 0.01% in the past hour. For longer-term performance, the price has ...

The Quarterly Results page of Dai Ichi Karkaria Ltd. presents the key result items, its comparison with the sector peers and its previous 5 Quarterly Results.